Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

Today's announcement marks the first TriNKET opt-in outside of oncology. Dragonfly to receive a $25 million payment and is eligible to...

Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target

Milestone payment to Dragonfly is triggered by dosing of first patient in Phase 1 clinical trial Dragonfly Therapeutics, Inc....

Dragonfly Therapeutics Expands Clinical Leadership Team

Appointing Dr. Hesham Aboshady as Head of Safety & Pharmacovigilance and Rajesh Israni as Head of Regulatory Affairs. Hesham Aboshady MD,...

Merck buzzes Dragonfly for 2nd immunotherapy candidate in $700M pact

The dragon is flying high today as Merck hits go on a second immunotherapy candidate from its $700 million pact with Dragonfly...

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients

Merck executes option to license its second immunotherapy candidate from the companies' 2018 collaboration for solid tumor targets....

Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate

Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago.

Merck opts in for Dragonfly's TriNKET cancer immunotherapy program

The U.S. Big Pharma is getting its hands on its first TriNKET immunotherapy candidate from the biotech, which comes after the pair...

Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy

Bristol Myers Squibb is paying nearly half a billion dollars in up front and near-term payments to license an early-stage immunotherapy...

Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program

By Ben Adams Bristol Myers Squibb is paying nearly half a billion in near-term and upfronts to licence Dragonfly Therapeutics’...

Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

Bristol Myers Squibb likes what it sees from the immune cell research of Dragonfly Therapeutics so far—enough to pay $55 million to add...

Doing deals in a time of coronavirus

Biotech CEO Bill Haney says 'you focus on the things that make a difference' Fidelity Management and Research has led a new round for...

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home

Today they’re making their first foray into human studies, with the launch of a Phase I study for their lead drug DF1001 in HER2...

Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™

Dragonfly also announced this week its first TriNKET, HER2-targeting DF1001, entered Phase 2. In its Phase 1 study DF1001 was...

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engage

Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of...

Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat

Two years ago, Bristol Myers Squibb R&D boss Rupert Vessey unveiled one of the biggest cash deals he’d done, focusing on the high-risk,...

Merck hits 'go' on a second Dragonfly drug

Merck & Co. Inc. has decided to move forward on its option to license a second drug from Waltham-based Dragonfly Therapeutics. The two...

Dragonfly Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer

The company announces that its lead TriNKET™ immunotherapy program DF1001, a HER2-targeted NK cell engager therapy...

AbbVie selects target for Dragonfly partnership

Dragonfly’s partnership with AbbVie is beginning to bear fruit.

Merck’s Roger Perlmutter buys his first solid tumor TriNKET from Dragonfly

A little more than 2 years after Merck’s Roger Perlmutter signed off on a deal that would pay Dragonfly up to $695 million for each drug...

Aiming for immunotherapy boost, Bristol Myers deepens ties with Dragonfly

Dive Brief: Bristol Myers Squibb has licensed from privately held biotech Dragonfly Therapeutics an experimental immunotherapy that it...

Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License

For Dragonfly’s IL-12 Investigational Immunotherapy Program Agreement Includes DF6002, With Potential to Advance Treatment of Solid...

A booming Dragonfly is taking its TriNKETs to Copenhagen

As the latest Bristol Myers pact spurs expansion plans -- outside the US Bristol Myers Squibb is making a habit out of collaborating with...

AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player

Bill Haney is building on his rep as one of the most prolific dealmakers in preclinical R&D, adding a new alliance for Dragonfly...

Dragonfly Therapeutics in $695M cancer R&D pact with Merck

More than a year after insect-inspired biotech Dragonfly Therapeutics penned a blood cancer pact with big biotech Celgene, it's back at...

Dragonfly Initiates Phase 2 Study of HER2 Targeting TriNKET™ DF1001

In Phase 1 DF1001 was well-tolerated and showed encouraging pharmacodynamic effects and clinical response, with tumor burden reductions...

Dragonfly Announces Multi-Target Expansion of Research Collaboration with AbbVie

Dragonfly and AbbVie expand their existing collaboration in oncology and autoimmune disease to develop additional drug candidates in...

Merck and Dragonfly, Together Again

This morning, investors in privately-held Dragonfly Therapeutics are thankful after Merck opted to license its second TriNKET...

Dragonfly gets Merck on second TriNKET candidate since 2018 collab

Dragonfly Therapeutics is doing better and better in getting Big Pharma on its TriNKET platform. First Celgene, then BMS, and now Merck —...

Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb

The company announces its sixth drug licensed by Bristol Myers Squibb, and the first patients enrolled and dosed in Phase 1 clinical...

Special report: Twenty extraordinary women blazing trails in biopharma R&D — Covid-19 and beyond

In the second year of Endpoints News’  budding tradition of highlighting women blazing trails in biopharma R&D, we’ve seen a number of...

Dragonfly Therapeutics Expands Leadership Team with Chief Operating Officer

and also Strengthens Scientific Advisory Board WALTHAM, Mass., Nov. 24, 2020 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly" or...

Bristol Myers bets $475M cash on a blockbuster shot at breaking the mold in immuno-oncology

With a potential IL-12 game-changer This morning Bristol Myers R&D maestro Rupert Vessey is taking the wraps off one of the biggest cash...

Dragonfly Therapeutics Announces BMS Opt-In of Fourth TriNKET™ Immunotherapy Drug Candidate

Published: Aug 10, 2020 WALTHAM, Mass., Aug. 10, 2020 /PRNewswire/ -- Dragonfly Therapeutics, Inc.. ("Dragonfly" or the "Company"), today...

Dragonfly Therapeutics Appoints Head of Clinical Development

Published: May 11, 2020 Tapan Maniar M.D. with 10+ years of biotech and pharma experience has been appointed head of clinical development...

Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors

WALTHAM, Mass., Nov. 12, 2019 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel...

Merck’s cancer R&D juggernaut ties up to little Dragonfly’s natural born killer platform

with billions on the line A little more than a year after Celgene bellied up to the partnership table with $33 million in cash to ally...